지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.1
- 수록면
- 1,394 - 1,399 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: Factor XIII (FXIII), a thrombin-activated plasma transglutaminase zymogen,is involved in cancer development and progression through a triggered coagulation pathway. The aim of this study was to examine whether FXIII activity levels differed in non-small cell lung cancer (NSCLC) patients according to histological types and TNM stage when compared with healthy subjects. Materials and Methods: Twenty-eight NSCLC patients and 28 normal controls who had been individually age-, gender-, body mass index-, smoking status-, and smoking amount-matched were enrolled: 13 adenocarcinomas, 11 squamous cell carcinomas, and four undifferentiated NSCLCs; four stage I, two stage II, 12 stage III, and 10 stage IV NSCLCs. FXIII activity was measured using fluorescence-based protein arrays. Results: The median FXIII activity level of the NSCLC group [24.2 Loewy U/mL, interquartile range (IQR) 14.9-40.4 Loewy U/mL] was significantly higher than that of the healthy group (17.5 Loewy U/mL, IQR 12.6-26.4 Loewy U/mL) (p=0.01). There were no differences in FXIII activity between adenocarcinoma (median 18.6 Loewy U/mL) and squamous cell carcinoma (median 28.7 Loewy U/mL). NSCLC stage significantly influenced FXIII activity (p=0.02). The FXIII activity of patients with stage III NSCLC (median 27.3 Loewy U/mL, IQR 19.3-40.5 Loewy U/mL) was significantly higher than those of patients with stage I or II (median 14.0 Loewy U/mL, IQR 13.1-23.1 Loewy U/mL, p=0.04). FXIII activity was negatively correlated with aPTT in NSCLC patients (r=-0.38, p=0.04). Conclusion: Patients with advanced-stage NSCLC exhibited higher coagulation FXIII activity than healthy controls and early-stage NSCLC patients.
목차
등록된 정보가 없습니다.
참고문헌 (27)
참고문헌 신청
Adany R / 2003 / Factor XIII subunit A as an intracellular transglutaminase / Cell Mol Life Sci 60 : 1049 ~ 1060
An Y / 2010 / Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma / Dis Markers 29 : 11 ~ 20
Bobek V / 2004 / Antitumor and antimetastatic effect of warfarin and heparins / Biomed Pharmacother 58 : 213 ~ 219
Camerer E / 2004 / Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis / Blood 104 : 397 ~ 401
Coate LE / 2009 / Molecular predictive and prognostic markers in non-small-cell lung cancer / Lancet Oncol 10 : 1001 ~ 1010
An Y / 2010 / Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma / Dis Markers 29 : 11 ~ 20
Bobek V / 2004 / Antitumor and antimetastatic effect of warfarin and heparins / Biomed Pharmacother 58 : 213 ~ 219
Camerer E / 2004 / Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis / Blood 104 : 397 ~ 401
Coate LE / 2009 / Molecular predictive and prognostic markers in non-small-cell lung cancer / Lancet Oncol 10 : 1001 ~ 1010
이 논문의 저자 정보
최근 본 자료
댓글(0)
0